Allspring Global Investments Holdings LLC Sells 40,269 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Allspring Global Investments Holdings LLC lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 77.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,593 shares of the company’s stock after selling 40,269 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Hims & Hers Health were worth $292,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares during the period. Geode Capital Management LLC increased its position in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after buying an additional 482,177 shares during the period. Blueshift Asset Management LLC raised its stake in Hims & Hers Health by 834.8% during the third quarter. Blueshift Asset Management LLC now owns 245,013 shares of the company’s stock worth $4,513,000 after buying an additional 218,804 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Hims & Hers Health by 15.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after buying an additional 218,566 shares during the period. Finally, State Street Corp boosted its position in Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after acquiring an additional 206,078 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Leerink Partners lifted their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Citigroup increased their price target on Hims & Hers Health from $25.00 to $27.00 and gave the stock a “sell” rating in a report on Tuesday. Bank of America lifted their price objective on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research note on Thursday, February 20th. Finally, Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $33.40.

Hims & Hers Health Trading Down 22.1 %

NYSE HIMS opened at $39.95 on Wednesday. The business has a fifty day simple moving average of $35.62 and a 200 day simple moving average of $26.25. Hims & Hers Health, Inc. has a 12 month low of $9.67 and a 12 month high of $72.98. The firm has a market capitalization of $8.73 billion, a P/E ratio of 90.79 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the transaction, the insider now owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now directly owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,578 shares of company stock valued at $38,080,320 in the last 90 days. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.